Viral Hepatitis C
10
2
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
20%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF
Serious Game Interventions to Reduce Viral Hepatitis C Among PLWH-MSM
Autoantibodies and Direct-acting Antivirals
DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)
Therapeutic Option for Hepatitis B and C: a French Cohort
Re-linkage to Care of Patients With Hepatitis C
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers